Vident Advisory, LLC
- SEC CIK
- 0001744347
- Latest filing
- Aug 12, 2026
RXRX holding history
Recursion Pharmaceuticals, Inc. in every 13F filed by Vident Advisory, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RXRX overviewAll 13F holders of RXRXFull Q2 2026 holdings
- Shares (Q2 2026)
- 17,660
- Value
- $64.8K
- % of portfolio
- <0.1%
- Quarters held
- 8
- Since Q3 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 17,660 | $64.8K | <0.1% | +3,611+25.7% | Added | Holders |
| Q1 2026 | 14,049 | $43.1K | <0.1% | +14,049 | New | Holders |
| Q2 2025 | 0 | $0 | 0.0% | −10,125−100.0% | Sold out | Holders |
| Q1 2025 | 10,125 | $53.6K | <0.1% | −1,647−14.0% | Reduced | Holders |
| Q4 2024 | 11,772 | $79.6K | <0.1% | +11,772 | New | Holders |
| Q3 2024 | 0 | $0 | 0.0% | −18,363−100.0% | Sold out | Holders |
| Q2 2024 | 18,363 | $137.7K | <0.1% | −398−2.1% | Reduced | Holders |
| Q1 2024 | 18,761 | $187.0K | <0.1% | −1,007−5.1% | Reduced | Holders |
| Q4 2023 | 19,768 | $194.9K | <0.1% | −7,381−27.2% | Reduced | Holders |
| Q3 2023 | 27,149 | $207.7K | <0.1% | – | No prior filing | Holders |